Pursuant to clause 33 of the Listing Obligations and Disclosure requirements (LODR), Regulations, 2015, GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the company will be held on Monday, 4th February, 2019, to consider and approve Un-Audited Financial Results for the quarter and nine months ended 31st December, 2018.
The above information is a part of company’s filings submitted to BSE.